WO2023187067 - FORMULATION METHOD
National phase entry:
Publication Number
WO/2023/187067
Publication Date
05.10.2023
International Application No.
PCT/EP2023/058317
International Filing Date
30.03.2023
Title **
[English]
FORMULATION METHOD
[French]
PROCÉDÉ DE FORMULATION
Applicants **
NOVO NORDISK A/S
Novo Allé 1
2880 Bagsværd, DK
Inventors
HANSEN, Rosa Rebecca Erritzøe
Novo Alle 1
2880 Bagsværd, DK
KJELDSEN, Benjamin Troest
Novo Alle 1
2880 Bagsværd, DK
Priority Data
22165607.7
30.03.2022
EP
22191564.8
22.08.2022
EP
P20220103410
13.12.2022
AR
PCT/EP2022/085558
13.12.2022
EP
836/2022
13.12.2022
PK
111147761
13.12.2022
TW
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1953 | |
| EPO | Filing, Examination | 6180 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 737 | |
| USA | Filing, Examination | 3160 |
Total: 12620 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Disclosed herein is a method of co-formulating an amylin receptor agonist and a GLP-1 receptor agonist. Disclosed herein is a liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist and a cyclodextrin comprising hydroxypropyl substitutions. Said co-formulation may be used for the medical treatment of subjects with overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated comorbidities; cardiovascular diseases, non-alcoholic steatohepatitis (NASH) and cognitive impairment, such as that caused by Alzheimer's disease.[French]
L'invention concerne un procédé de co-formulation d'un agoniste du récepteur de l'amyline et d'un agoniste du récepteur GLP-1. L'invention concerne une formulation pharmaceutique liquide comprenant un agoniste du récepteur de l'amyline, un agoniste du récepteur GLP-1 et une cyclodextrine comprenant des substitutions hydroxypropyle. Ladite co-formulation peut être utilisée pour le traitement médical de sujets présentant les maladies ou troubles suivants : surpoids ou obésité, avec ou sans comorbidités associées; diabète, avec ou sans comorbidités associées; maladies cardiovasculaires, stéatohépatite non alcoolique (NASH) et troubles cognitifs, tels que ceux provoqués par la maladie d'Alzheimer.